Susan P C Cole

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/751996/publications.pdf

Version: 2024-02-01

187 papers 17,666 citations

19636 61 h-index 128 g-index

188 all docs

188
docs citations

188 times ranked 10394 citing authors

#	Article	IF	CITATIONS
1	GSH facilitates the binding and inhibitory activity of novel multidrug resistance protein 1 (MRP1) modulators. FEBS Journal, 2022, 289, 3854-3875.	2.2	6
2	Conserved amino acids in the region connecting membrane spanning domain 1 to nucleotide binding domain 1 are essential for expression of the MRP1 (ABCC1) transporter. PLoS ONE, 2021, 16, e0246727.	1.1	2
3	Mutagenic Analysis of the Putative ABCC6 Substrate-Binding Cavity Using a New Homology Model. International Journal of Molecular Sciences, 2021, 22, 6910.	1.8	8
4	The First Cytoplasmic Loop in the Core Structure of the ABCC1 (Multidrug Resistance Protein 1; MRP1) Transporter Contains Multiple Amino Acids Essential for Its Expression. International Journal of Molecular Sciences, 2021, 22, 9710.	1.8	1
5	MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells. Biochemical Pharmacology, 2019, 168, 237-248.	2.0	29
6	Structureâ€guided probing of the leukotriene C ₄ binding site in human multidrug resistance protein 1 (MRP1; ABCC1). FASEB Journal, 2019, 33, 10692-10704.	0.2	21
7	A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity. Cell Reports, 2019, 26, 1544-1556.e8.	2.9	146
8	Preparation of psoralen polymer–lipid hybrid nanoparticles and their reversal of multidrug resistance in MCF-7/ADR cells. Drug Delivery, 2018, 25, 1044-1054.	2.5	21
9	An Outward-Facing Aromatic Amino Acid Is Crucial for Signaling between the Membrane-Spanning and Nucleotide-Binding Domains of Multidrug Resistance Protein 1 (MRP1; ABCC1). Molecular Pharmacology, 2018, 94, 1069-1078.	1.0	16
10	Preparation and evaluation of spirulina polysaccharide nanoemulsions. International Journal of Molecular Medicine, 2018, 42, 1273-1282.	1.8	6
11	Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells. Oncology Reports, 2018, 40, 1055-1063.	1.2	10
12	Effect of traditional Chinese medicine components on multidrug resistance in tumors mediated by P-glycoprotein. Oncology Letters, 2017, 13, 3989-3996.	0.8	18
13	A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. Nanomaterials, 2017, 7, 122.	1.9	147
14	Arsenic Triglutathione [As(GS) ₃] Transport by Multidrug Resistance Protein 1 (MRP1/ <i>ABCC1</i>) Is Selectively Modified by Phosphorylation of Tyr920/Ser921 and Glycosylation of Asn19/Asn23. Molecular Pharmacology, 2016, 90, 127-139.	1.0	21
15	Polymorphic variants of MRP4/ABCC4 differentially modulate the transport of methylated arsenic metabolites and physiological organic anions. Biochemical Pharmacology, 2016, 120, 72-82.	2.0	32
16	Cysteinyl Leukotriene Receptor 1/2 Antagonists Nonselectively Modulate Organic Anion Transport by Multidrug Resistance Proteins (MRP1-4). Drug Metabolism and Disposition, 2016, 44, 857-866.	1.7	21
17	Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer. Oncology Letters, 2016, 12, 11-15.	0.8	54
18	N-linked glycans do not affect plasma membrane localization of multidrug resistance protein 4 (MRP4) but selectively alter its prostaglandin E2 transport activity. Biochemical and Biophysical Research Communications, 2016, 469, 954-959.	1.0	12

#	Article	IF	Citations
19	Multidrug Resistance Protein 1 (MRP1, ABCC1), a "Multitasking―ATP-binding Cassette (ABC) Transporter. Journal of Biological Chemistry, 2014, 289, 30880-30888.	1.6	265
20	Na+/H+ Exchanger Regulatory Factor 3 Is Critical for Multidrug Resistance Protein 4–Mediated Drug Efflux in the Kidney. Journal of the American Society of Nephrology: JASN, 2014, 25, 726-736.	3.0	26
21	Targeting Multidrug Resistance Protein 1 (MRP1, <i>ABCC1</i>): Past, Present, and Future. Annual Review of Pharmacology and Toxicology, 2014, 54, 95-117.	4.2	267
22	Prostaglandin signalling regulates ciliogenesis by modulating intraflagellar transport. Nature Cell Biology, 2014, 16, 841-851.	4.6	84
23	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). Biochemical Pharmacology, 2014, 91, 97-108.	2.0	53
24	Differential functional rescue of Lys513 and Lys516 processing mutants of MRP1 (ABCC1) by chemical chaperones reveals different domain–domain interactions of the transporter. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 756-765.	1.4	12
25	Two Polymorphic Variants of ABCC1 Selectively Alter Drug Resistance and Inhibitor Sensitivity of the Multidrug and Organic Anion Transporter Multidrug Resistance Protein 1. Drug Metabolism and Disposition, 2013, 41, 2187-2196.	1.7	22
26	Chalcogenopyrylium Dyes as Differential Modulators of Organic Anion Transport by Multidrug Resistance Protein 1 (MRP1), MRP2, and MRP4. Drug Metabolism and Disposition, 2013, 41, 1231-1239.	1.7	16
27	Mutation of Glu521 or Glu535 in Cytoplasmic Loop 5 Causes Differential Misfolding in Multiple Domains of Multidrug and Organic Anion Transporter MRP1 (ABCC1). Journal of Biological Chemistry, 2012, 287, 7543-7555.	1.6	27
28	Mechanism of RPE Cell Death in $\hat{l}\pm$ -Crystallin Deficient Mice: A Novel and Critical Role for MRP1-Mediated GSH Efflux. PLoS ONE, 2012, 7, e33420.	1.1	52
29	Chalcogenopyrylium Compounds as Modulators of the ATP-Binding Cassette Transporters P-Glycoprotein (P-gp/ <i>ABCB1</i>) and Multidrug Resistance Protein 1 (MRP1/ <i>ABCC1</i>). Journal of Medicinal Chemistry, 2012, 55, 4683-4699.	2.9	39
30	Expression and Function of Human MRP1 (ABCC1) Is Dependent on Amino Acids in Cytoplasmic Loop 5 and Its Interface with Nucleotide Binding Domain 2. Journal of Biological Chemistry, 2011, 286, 7202-7213.	1.6	29
31	ABCC1 G2012T single nucleotide polymorphism is associated with patient outcome in primary neuroblastoma and altered stability of the ABCC1 gene transcript. Pharmacogenetics and Genomics, 2011, 21, 270-279.	0.7	23
32	Mammalian multidrug-resistance proteins (MRPs). Essays in Biochemistry, 2011, 50, 179-207.	2.1	184
33	Regulation of Arsenic Triglutathione [As(GS) 3] Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1) Through Postâ€translational Modification. FASEB Journal, 2011, 25, lb502.	0.2	0
34	MRP1 Polymorphisms Associated With Citalopram Response in Patients With Major Depression. Journal of Clinical Psychopharmacology, 2010, 30, 116-125.	0.7	35
35	A new series of titanocene dichloride derivatives bearing chiral alkylammonium groups; assessment of their cytotoxic properties. Inorganica Chimica Acta, 2010, 364, 16-22.	1.2	15
36	Structure of a human multidrug transporter in an inward-facing conformation. Journal of Structural Biology, 2010, 170, 540-547.	1.3	28

3

#	Article	IF	Citations
37	Multiple Roles of Charged Amino Acids in Cytoplasmic Loop 7 for Expression and Function of the Multidrug and Organic Anion Transporter MRP1 (ABCC1). Molecular Pharmacology, 2009, 75, 397-406.	1.0	24
38	Molecular Basis for Reduced Estrone Sulfate Transport and Altered Modulator Sensitivity of Transmembrane Helix (TM) 6 and TM17 Mutants of Multidrug Resistance Protein 1 (ABCC1). Drug Metabolism and Disposition, 2009, 37, 1411-1420.	1.7	40
39	Involvement of NHERF1 in apical membrane localization of MRP4 in polarized kidney cells. Biochemical and Biophysical Research Communications, 2009, 379, 60-64.	1.0	44
40	Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. Biochemical Pharmacology, 2008, 75, 1659-1669.	2.0	14
41	Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemical and Biophysical Research Communications, 2008, 365, 29-34.	1.0	70
42	Residues Responsible for the Asymmetric Function of the Nucleotide Binding Domains of Multidrug Resistance Protein 1. Biochemistry, 2008, 47, 13952-13965.	1.2	22
43	Down-regulation of Na+/H+ Exchanger Regulatory Factor 1 Increases Expression and Function of Multidrug Resistance Protein 4. Cancer Research, 2008, 68, 4802-4809.	0.4	42
44	Identification of Regions Required for Apical Membrane Localization of Human Multidrug Resistance Protein 2. Molecular Pharmacology, 2008, 74, 9-19.	1.0	51
45	Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metabolism and Disposition, 2008, 36, 2571-2581.	1.7	40
46	Mechanistic Differences between GSH Transport by Multidrug Resistance Protein 1 (MRP1/ABCC1) and GSH Modulation of MRP1-Mediated Transport. Molecular Pharmacology, 2008, 74, 1630-1640.	1.0	27
47	Modulation of Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) Transport Activities by Endogenous and Exogenous Glutathione-Conjugated Catechol Metabolites. Drug Metabolism and Disposition, 2008, 36, 552-560.	1.7	33
48	Nuclear interactions of topoisomerase II \hat{A} and \hat{A} with phospholipid scramblase 1. Nucleic Acids Research, 2007, 35, 4076-4085.	6. 5	27
49	Mutational Analysis of a Highly Conserved Proline Residue in MRP1, MRP2, and MRP3 Reveals a Partially Conserved Function. Drug Metabolism and Disposition, 2007, 35, 1372-1379.	1.7	20
50	A new series of titanocene dichloride derivatives bearing cyclic alkylammonium groups: Assessment of their cytotoxic properties. Journal of Organometallic Chemistry, 2007, 692, 3508-3518.	0.8	34
51	Topoisomerase II binds importin \hat{l}_{\pm} isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells. Experimental Cell Research, 2007, 313, 627-637.	1.2	15
52	Functional Importance of Three Basic Residues Clustered at the Cytosolic Interface of Transmembrane Helix 15 in the Multidrug and Organic Anion Transporter MRP1 (ABCC1). Journal of Biological Chemistry, 2006, 281, 43-50.	1.6	40
53	Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Letters, 2006, 580, 1103-1111.	1.3	237
54	Transport of glutathione and glutathione conjugates by MRP1. Trends in Pharmacological Sciences, 2006, 27, 438-446.	4.0	313

#	Article	IF	CITATIONS
55	Cellular toxicities of new titanocene dichloride derivatives containing pendant cyclic alkylammonium groups. Inorganic Chemistry Communication, 2006, 9, 1114-1116.	1.8	26
56	Drosophila dihydrofolate reductase mutations confer antifolate resistance to mammalian cells. European Journal of Pharmacology, 2006, 529, 71-78.	1.7	9
57	MUTATIONAL ANALYSIS OF POLAR AMINO ACID RESIDUES WITHIN PREDICTED TRANSMEMBRANE HELICES 10 AND 16 OF MULTIDRUG RESISTANCE PROTEIN 1 (ABCC1): EFFECT ON SUBSTRATE SPECIFICITY. Drug Metabolism and Disposition, 2006, 34, 539-546.	1.7	24
58	Role of GSH in Estrone Sulfate Binding and Translocation by the Multidrug Resistance Protein 1 (MRP1/ABCC1). Journal of Biological Chemistry, 2006, 281, 13906-13914.	1.6	50
59	Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiological Reviews, 2006, 86, 849-899.	13.1	679
60	Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenetics and Genomics, 2005, 15, 523-533.	0.7	78
61	Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenetics and Genomics, 2005, 15, 647-657.	0.7	77
62	Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas. Biochemical Pharmacology, 2005, 69, 451-461.	2.0	29
63	Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicology and Applied Pharmacology, 2005, 204, 216-237.	1.3	1,222
64	Analysis of Human Multidrug Resistance Protein 1 (ABCC1) by Matrix-Assisted Laser Desorption lonization/Time of Flight Mass Spectrometry: Toward Identification of Leukotriene C4 Binding Sites. Molecular Pharmacology, 2005, 68, 1455-1465.	1.0	27
65	Functional Interactions Between Nucleotide Binding Domains and Leukotriene C4 Binding Sites of Multidrug Resistance Protein 1 (ABCC1). Molecular Pharmacology, 2005, 67, 1944-1953.	1.0	25
66	Role of the NH2-terminal Membrane Spanning Domain of Multidrug Resistance Protein 1/ABCC1 in Protein Processing and Trafficking. Molecular Biology of the Cell, 2005, 16, 2483-2492.	0.9	71
67	Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. Toxicology Letters, 2005, 157, 9-19.	0.4	21
68	(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The MRP-Related and BCRP / ABCG2 Multidrug Resistance Proteins: Biology, Substrate Specificity and Regulation. Current Drug Metabolism, 2004, 5, 21-53.	0.7	469
69	Mutations of Charged Amino Acids in or near the Transmembrane Helices of the Second Membrane Spanning Domain Differentially Affect the Substrate Specificity and Transport Activity of the Multidrug Resistance Protein MRP1 (ABCC1). Molecular Pharmacology, 2004, 65, 1375-1385.	1.0	71
70	Molecular Modeling Correctly Predicts the Functional Importance of Phe594 in Transmembrane Helix 11 of the Multidrug Resistance Protein, MRP1 (ABCC1). Journal of Biological Chemistry, 2004, 279, 463-468.	1.6	60
71	Identification and Characterization of Functionally Important Elements in the Multidrug Resistance Protein 1 COOH-terminal Region. Journal of Biological Chemistry, 2004, 279, 53571-53583.	1.6	14
72	Identification of Proline Residues in the Core Cytoplasmic and Transmembrane Regions of Multidrug Resistance Protein 1 (MRP1/ABCC1) Important for Transport Function, Substrate Specificity, and Nucleotide Interactions. Journal of Biological Chemistry, 2004, 279, 12325-12336.	1.6	63

#	Article	IF	CITATIONS
73	Synthesis, Characterization, and Assessment of Cytotoxic Properties of a Series of Titanocene Dichloride Derivatives. Organometallics, 2004, 23, 4486-4494.	1.1	100
74	Mapping of the MRPm5 epitope to the cytosolic region between transmembrane helices 13 and 14 in the drug and organic anion transporter, MRP1 (ABCC1). Biochemical and Biophysical Research Communications, 2004, 315, 719-725.	1.0	7
75	Functional expression of the human breast cancer resistance protein in Pichia pastoris. Biochemical and Biophysical Research Communications, 2004, 320, 730-737.	1.0	33
76	Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1). Journal of Biological Chemistry, 2004, 279, 38871-38880.	1.6	41
77	Transmembrane Helix 11 of Multidrug Resistance Protein 1 (MRP1/ABCC1):  Identification of Polar Amino Acids Important for Substrate Specificity and Binding of ATP at Nucleotide Binding Domain 1. Biochemistry, 2004, 43, 9413-9425.	1.2	30
78	CFTR directly mediates nucleotide-regulated glutathione flux. EMBO Journal, 2003, 22, 1981-1989.	3.5	193
79	Characterization of the Role of Polar Amino Acid Residues within Predicted Transmembrane Helix 17 in Determining the Substrate Specificity of Multidrug Resistance Protein 3â€. Biochemistry, 2003, 42, 9989-10000.	1.2	33
80	Identification of the Structural and Functional Boundaries of the Multidrug Resistance Protein 1 Cytoplasmic Loop 3â€. Biochemistry, 2003, 42, 14099-14113.	1.2	48
81	Mutation of proline residues in the NH2-terminal region of the multidrug resistance protein, MRP1 (ABCC1): effects on protein expression, membrane localization, and transport function. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1615, 103-114.	1.4	20
82	Identification of functional nuclear export sequences in human topoisomerase IIÎ \pm and Î 2 . Biochemical and Biophysical Research Communications, 2003, 306, 905-911.	1.0	25
83	Role of Carboxylate Residues Adjacent to the Conserved Core Walker B Motifs in the Catalytic Cycle of Multidrug Resistance Protein 1 (ABCC1). Journal of Biological Chemistry, 2003, 278, 38537-38547.	1.6	72
84	MULTIDRUG RESISTANCE PROTEIN 1 (ABCC1)., 2003,, 393-422.		15
85	Functional and Structural Consequences of Cysteine Substitutions in the NH2Proximal Region of the Human Multidrug Resistance Protein 1 (MRP1/ABCC1)â€. Biochemistry, 2003, 42, 5214-5224.	1.2	73
86	A single point mutation in Drosophila dihydrofolate reductase confers methotrexate resistance to a transgenic CHO cell line. Genome, 2003, 46, 707-715.	0.9	4
87	Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1). Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 643-653.	1.3	50
88	Cloning and Characterization of the Murine and Rat mrp1 Promoter Regions. Molecular Pharmacology, 2003, 64, 1259-1269.	1.0	25
89	MOLECULAR CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF RAT MULTIDRUG RESISTANCE PROTEIN 1 (MRP1). Drug Metabolism and Disposition, 2003, 31, 1016-1026.	1.7	29
90	Functional Importance of Polar and Charged Amino Acid Residues in Transmembrane Helix 14 of Multidrug Resistance Protein 1 (MRP1/ABCC1). Journal of Biological Chemistry, 2003, 278, 46052-46063.	1.6	45

#	Article	IF	CITATIONS
91	Bioflavonoid Stimulation of Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1). Drug Metabolism and Disposition, 2003, 31, 11-15.	1.7	125
92	Substitution of Trp1242 of TM17 alters substrate specificity of human multidrug resistance protein 3. American Journal of Physiology - Renal Physiology, 2003, 284, G280-G289.	1.6	23
93	Charged Amino Acids in the Sixth Transmembrane Helix of Multidrug Resistance Protein 1 (MRP1/ABCC1) Are Critical Determinants of Transport Activity. Journal of Biological Chemistry, 2002, 277, 41326-41333.	1.6	65
94	Multiple Membrane-associated Tryptophan Residues Contribute to the Transport Activity and Substrate Specificity of the Human Multidrug Resistance Protein, MRP1. Journal of Biological Chemistry, 2002, 277, 49495-49503.	1.6	45
95	A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics and Genomics, 2002, 12, 321-330.	5.7	112
96	Characterization of the human topoisomerase Ill^2 (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites. Biochemical Journal, 2002, 368, 741-751.	1.7	25
97	Photolabeling of Human and Murine Multidrug Resistance Protein 1 with the High Affinity Inhibitor [1251]LY475776 and Azidophenacyl-[35S]Glutathione. Journal of Biological Chemistry, 2002, 277, 35225-35231.	1.6	42
98	Determinants of the Substrate Specificity of Multidrug Resistance Protein 1. Journal of Biological Chemistry, 2002, 277, 20934-20941.	1.6	43
99	GSH-dependent Photolabeling of Multidrug Resistance Protein MRP1 (ABCC1) by [1251]LY475776. Journal of Biological Chemistry, 2002, 277, 28690-28699.	1.6	52
100	Multidrug Resistance II: MRP and Related Proteins. , 2002, , 255-267.		1
101	Identification of a Nonconserved Amino Acid Residue in Multidrug Resistance Protein 1 Important for Determining Substrate Specificity. Journal of Biological Chemistry, 2001, 276, 34966-34974.	1.6	60
102	Identification of DNA–Protein Interactions in the 5′ Flanking and 5′ Untranslated Regions of the Human Multidrug Resistance Protein (MRP1) Gene: Evaluation of a Putative Antioxidant Response Element/AP-1 Binding Site. Biochemical and Biophysical Research Communications, 2001, 285, 981-990.	1.0	55
103	Subcellular Localization Analysis of the Closely Related Fps/Fes and Fer Protein-Tyrosine Kinases Suggests a Distinct Role for Fps/Fes in Vesicular Trafficking. Experimental Cell Research, 2001, 266, 87-94.	1.2	41
104	Mutation of Trp1254 in the Multispecific Organic Anion Transporter, Multidrug Resistance Protein 2 (MRP2) (ABCC2), Alters Substrate Specificity and Results in Loss of Methotrexate Transport Activity. Journal of Biological Chemistry, 2001, 276, 38108-38114.	1.6	111
105	Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. Journal of Human Genetics, 2001, 46, 656-663.	1.1	91
106	Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology, 2001, 167, 3-23.	2.0	364
107	Identification of an Amino Acid Residue in Multidrug Resistance Protein 1 Critical for Conferring Resistance to Anthracyclines. Journal of Biological Chemistry, 2001, 276, 13231-13239.	1.6	80
108	Transport of the \hat{I}^2 -O-Glucuronide Conjugate of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the Multidrug Resistance Protein 1 (MRP1). Journal of Biological Chemistry, 2001, 276, 27846-27854.	1.6	147

#	Article	IF	Citations
109	The Structure of the Multidrug Resistance Protein 1 (MRP1/ABCC1). Journal of Biological Chemistry, 2001, 276, 16076-16082.	1.6	141
110	Mutation of a Single Conserved Tryptophan in Multidrug Resistance Protein 1 (MRP1/ABCC1) Results in Loss of Drug Resistance and Selective Loss of Organic Anion Transport. Journal of Biological Chemistry, 2001, 276, 15616-15624.	1.6	138
111	Characterization of Binding of Leukotriene C4 by Human Multidrug Resistance Protein 1. Journal of Biological Chemistry, 2001, 276, 38636-38644.	1.6	56
112	Glutathione Stimulates Sulfated Estrogen Transport by Multidrug Resistance Protein 1. Journal of Biological Chemistry, 2001, 276, 6404-6411.	1.6	150
113	Modulation of Multidrug Resistance Protein 1 (MRP1/ABCC1) Transport and ATPase Activities by Interaction with Dietary Flavonoids. Molecular Pharmacology, 2001, 59, 1171-1180.	1.0	228
114	A truncated cytoplasmic topoisomerase $\hat{\text{III}}$ in a drug-resistant lung cancer cell line is encoded by aTOP2A allele with a partial deletion of exon 34., 2000, 85, 534-539.		20
115	Simultaneous Quantitation of Topoisomerase II \hat{l}_{\pm} and \hat{l}^{2} Isoform mRNAs in Lung Tumor Cells and Normal and Malignant Lung Tissue. Laboratory Investigation, 2000, 80, 787-795.	1.7	13
116	The Multidrug Resistance Protein 1: A Functionally Important Activation Marker for Murine Th1 Cells. Journal of Immunology, 2000, 164, 754-761.	0.4	38
117	Functional Reconstitution of Substrate Transport by Purified Multidrug Resistance Protein MRP1 (ABCC1) in Phospholipid Vesicles. Journal of Biological Chemistry, 2000, 275, 34166-34172.	1.6	83
118	Comparison of the Functional Characteristics of the Nucleotide Binding Domains of Multidrug Resistance Protein 1. Journal of Biological Chemistry, 2000, 275, 13098-13108.	1.6	158
119	Structure–Activity Studies of Verapamil Analogs That Modulate Transport of Leukotriene C4 and Reduced Glutathione by Multidrug Resistance Protein MRP1. Biochemical and Biophysical Research Communications, 2000, 275, 795-803.	1.0	56
120	Monoclonal Antibodies That Inhibit the Transport Function of the 190-kDa Multidrug Resistance Protein, MRP. Journal of Biological Chemistry, 1999, 274, 15420-15426.	1.6	71
121	Localization of a Substrate Specificity Domain in the Multidrug Resistance Protein. Journal of Biological Chemistry, 1999, 274, 22877-22883.	1.6	52
122	Retrovirus-Mediated Gene Transfer of the Human Multidrug Resistance-Associated Protein into Hematopoietic Cells Protects Mice from Chemotherapy-Induced Leukopenia. Human Gene Therapy, 1999, 10, 801-811.	1.4	20
123	ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 69-82.	1.4	89
124	Structural, mechanistic and clinical aspects of MRP1. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1461, 359-376.	1.4	350
125	Sequence Determinants of Nuclear Localization in the \hat{l}_{\pm} and \hat{l}_{\pm}^2 Isoforms of Human Topoisomerase II. Experimental Cell Research, 1999, 251, 329-339.	1.2	42
126	Expression of multidrug resistance protein gene in patients with glioma after chemotherapy. Journal of Neuro-Oncology, 1998, 40, 11-18.	1.4	83

#	Article	IF	CITATIONS
127	Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP). British Journal of Cancer, 1998, 78, 1134-1140.	2.9	69
128	Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. BioEssays, 1998, 20, 931-940.	1.2	305
129	Structural organization of the human TOP2A and TOP2B genes. Gene, 1998, 221, 255-266.	1.0	56
130	Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Letters, 1998, 130, 133-141.	3.2	23
131	Multidrug Resistance Protein. Journal of Biological Chemistry, 1998, 273, 10733-10740.	1.6	81
132	[44] Cloning, transfer, and characterization of multidrug resistance protein. Methods in Enzymology, 1998, 292, 594-607.	0.4	2
133	A multidrug-resistance protein (MRP)-like transmembrane pump is highly expressed by resting murine T helper (Th) 2, but not Th1 cells, and is induced to equal expression levels in Th1 and Th2 cells after antigenic stimulation in vivo Journal of Clinical Investigation, 1998, 101, 703-710.	3.9	40
134	Pharmacological Characterization of the Murine and Human Orthologs of Multidrug-Resistance Protein in Transfected Human Embryonic Kidney Cells. Molecular Pharmacology, 1997, 52, 344-353.	1.0	127
135	Membrane Topology of the Multidrug Resistance Protein (MRP). Journal of Biological Chemistry, 1997, 272, 23623-23630.	1.6	189
136	ATP-Dependent Transport of Aflatoxin B1 and Its Glutathione Conjugates by the Product of the Multidrug Resistance Protein (MRP) Gene. Molecular Pharmacology, 1997, 51, 1034-1041.	1.0	193
137	Two COOH-Terminal Truncated Cytoplasmic Forms of Topoisomerase IIα in a VP-16-Selected Lung Cancer Cell Line Result from Partial Gene Deletion and Alternative Splicingâ€. Biochemistry, 1997, 36, 5868-5877.	1.2	30
138	Clinical Significance of Multi-Drug Resistance Associated Protein and P-Glycoprotein in Patients with Bladder Cancer. Journal of Urology, 1997, 157, 1260-1265.	0.2	64
139	Bipartite Nuclear Localization Signals in the C Terminus of Human Topoisomerase IIα. Experimental Cell Research, 1997, 237, 452-455.	1.2	53
140	Analysis of the Intron–Exon Organization of the Human Multidrug-Resistance Protein Gene (MRP) and Alternative Splicing of Its mRNA. Genomics, 1997, 45, 368-378.	1.3	85
141	Evidence that the MYCN oncogene regulates MRP gene expression in neuroblastoma. European Journal of Cancer, 1997, 33, 1911-1916.	1.3	48
142	Standardization of a single-cell assay for sensitive detection of multidrug resistance protein expression in normal and malignant cells in archival clinical samples. Translational Research, 1997, 130, 297-306.	2.4	5
143	Function, evolution and structure of multidrug resistance protein (MRP). Seminars in Cancer Biology, 1997, 8, 193-204.	4.3	144
144	Biology of the multidrug resistance-associated protein, MRP. European Journal of Cancer, 1996, 32, 945-957.	1.3	341

#	Article	IF	CITATIONS
145	Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochemical Pharmacology, 1996, 51, 461-469.	2.0	78
146	Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochemical Pharmacology, 1996, 52, 967-977.	2.0	227
147	Functional Expression of the Multidrug Resistance-associated Protein in the Yeast Saccharomyces cerevisiae. Journal of Biological Chemistry, 1996, 271, 4154-4160.	1.6	34
148	ATP-dependent glutathione disulphide transport mediated by the <i>MRP</i> gene-encoded conjugate export pump. Biochemical Journal, 1996, 314, 433-437.	1.7	272
149	ATP-dependent $17\hat{l}^2$ -Estradiol 17-(\hat{l}^2 -D-Glucuronide) Transport by Multidrug Resistance Protein (MRP). Journal of Biological Chemistry, 1996, 271, 9683-9689.	1.6	224
150	Multidrug Resistance Protein (MRP)-mediated Transport of Leukotriene C4 and Chemotherapeutic Agents in Membrane Vesicles. Journal of Biological Chemistry, 1996, 271, 9675-9682.	1.6	443
151	Reconstitution of ATP-dependent Leukotriene C4 Transport by Co-expression of Both Half-molecules of Human Multidrug Resistance Protein in Insect Cells. Journal of Biological Chemistry, 1996, 271, 27782-27787.	1.6	124
152	The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias. Leukemia and Lymphoma, 1996, 20, 357-364.	0.6	16
153	Multidrug Resistance Associated with Overexpression of MRP. Cancer Treatment and Research, 1996, 87, 39-62.	0.2	26
154	Synthesis and cytotoxic evaluation of some styryl ketones and related compounds. European Journal of Medicinal Chemistry, 1995, 30, 209-217.	2.6	24
155	Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. International Journal of Cancer, 1994, 57, 522-528.	2.3	34
156	Reduced levels of topoisomerase II? and II? in a multidrug-resistant lung-cancer cell line. Cancer Chemotherapy and Pharmacology, 1994, 34, 242-248.	1.1	27
157	Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet, The, 1994, 343, 1531-1534.	6.3	104
158	Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somatic Cell and Molecular Genetics, 1994, 20, 423-435.	0.7	38
159	Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines?. British Journal of Cancer, 1993, 68, 327-335.	2.9	31
160	Elevated expression of Annexin II (Lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line. British Journal of Cancer, 1992, 65, 498-502.	2.9	85
161	Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258, 1650-1654.	6.0	2,946
162	The 1991 Merck Frosst Award. Multidrug resistance in small cell lung cancer. Canadian Journal of Physiology and Pharmacology, 1992, 70, 313-329.	0.7	51

#	Article	IF	Citations
163	Tumourigenic multidrug-resistant HT1080 cells do not overexpress receptors for epidermal growth factor. British Journal of Cancer, 1991, 64, 296-298.	2.9	6
164	Chemosensitivity testing of small cell lung cancer using the MTT assay. British Journal of Cancer, 1991, 63, 75-83.	2.9	116
165	Multidrug resistance-associated antigens on drug-sensitive and -resistant human tumour cell lines. British Journal of Cancer, 1991, 64, 15-22.	2.9	14
166	Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant. Cancer Immunology, Immunotherapy, 1991, 33, 274-277.	2.0	7
167	A monoclonal antibody detecting cell surface epitope on some drug resistant human tumour cell lines. British Journal of Cancer, 1990, 62, 14-16.	2.9	7
168	Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemotherapy and Pharmacology, 1990, 26, 250-256.	1.1	45
169	Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. British Journal of Cancer, 1989, 59, 42-46.	2.9	94
170	Use of the mtt assay for rapid determination of chemosensitivity of human leukemic blast cells. Leukemia Research, 1988, 12, 823-831.	0.4	123
171	Growth of human × human hybridomas in protein-free medium supplemented with ethanolamine. Journal of Immunological Methods, 1987, 97, 29-35.	0.6	18
172	[11] Comparative phenotypic analysis of available human hybridoma fusion partners. Methods in Enzymology, 1986, 121, 120-140.	0.4	10
173	Establishment of a human large cell lung tumor line (QU-DB) with metastatic properties in athymic mice. Cancer, 1986, 58, 917-923.	2.0	30
174	Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemotherapy and Pharmacology, 1986, 17, 259-63.	1.1	262
175	[12] The EBV-hybridoma technique. Methods in Enzymology, 1986, 121, 140-167.	0.4	37
176	Two-dimensional electrophoretic display of restriction fragments from genomic DNA. Analytical Biochemistry, 1985, 149, 177-182.	1.1	7
177	Antibody production by human \tilde{A} — human hybridomas in serum-free medium. Journal of Immunological Methods, 1985, 78, 271-278.	0.6	14
178	Specific immunoglobulin production and enhanced tumorigenicity following ascites growth of human hybridomas. Journal of Immunological Methods, 1985, 81, 31-42.	0.6	19
179	Ferrochelatase and N-alkylated porphyrins. Molecular and Cellular Biochemistry, 1984, 64, 127-37.	1.4	30
180	Human monoclonal antibodies. Molecular and Cellular Biochemistry, 1984, 62, 109-20.	1.4	47

#	Article	IF	CITATIONS
181	Alterations in the heme biosynthetic pathway as an index of exposure to toxins. Canadian Journal of Physiology and Pharmacology, 1982, 60, 1017-1026.	0.7	13
182	Inhibition of ferrochelatase by N-methylprotoporphyrin IX is not accompanied by δ-aminolevulinic acid synthetase induction in chick embryo liver cell culture. Canadian Journal of Physiology and Pharmacology, 1982, 60, 212-215.	0.7	3
183	Effects of porphyrin-inducing drugs on ferrochelatase activity in isolated mouse hepatocytes. Canadian Journal of Physiology and Pharmacology, 1981, 59, 1155-1158.	0.7	7
184	Differential inhibition of hepatic ferrochelatase by the isomers of N-ethylprotoporphyrin IX. Biochemical and Biophysical Research Communications, 1981, 103, 581-586.	1.0	35
185	Structural requirements in dihydropyridines for ferrochelatase inhibition and $\hat{\Gamma}$ -aminolevulinic acid synthetase induction. International Journal of Biochemistry & Cell Biology, 1980, 12, 989-992.	0.8	8
186	Inhibition of hepatic ferrochelatase by the four isomers of N-methylprotoporphyrin IX. Biochemical and Biophysical Research Communications, 1980, 97, 1436-1442.	1.0	33
187	Drug-induced porphyrin biosynthesis—XIX. Biochemical Pharmacology, 1979, 28, 3533-3538.	2.0	29